NY-SLICE/SOMPO
16.1.2020 15:17:05 CET | Business Wire | Press release
Slice Labs Inc. (Slice) , the first on-demand insurance platform and Sompo Holdings (Asia) Pte. Ltd. (SOMPO) – part of top international insurer Sompo Holdings, have released an enhanced version of the travel insurance product, TravelJoy, in Thailand using social distribution through LINE LIFF Platform making on-demand trip protection services available to 44 million LINE users in the country.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200116005045/en/
“SOMPO’s partnership with Slice and relationship with LINE blend a common commitment to introduce more convenient and user-friendly digital services that best aid Thailand’s increasingly cashless society,” commented Patrick Chin, Head of Digital and Branding, Asia Pacific at SOMPO. “We believe in meeting customers where they are at with innovative technologies that support their lifestyles. Slice ICS is an incredible asset that has positioned SOMPO to develop and implement a progressive product solution within a short timeframe.”
Sompo Insurance Thailand (Sompo Thailand) CEO, Chayanna Siripirom echoed, “More than 90% of Thailand’s mobile internet users are using LINE commercially and socially. Now that TravelJoy is made available on our very own LINE OA, we can offer better services and solutions to our customers, as well as reach out to a larger market.”
The joint travel insurance product, TravelJoy, will include life and medical, flight delay/cancellation, and baggage/belongings coverage. As part of the offering, Slice ICS will integrate with pan-Asian payments provider, 2C2P, that serves 620 million banked and unbanked Southeast Asia customers. Available in English and Thai, the Slice and SOMPO TravelJoy is purchased via Sompo Thailand LINE Official Account on the LINE platform in under three minutes and costs ₿500 (Thai baht) (USD16) per average customer.
“This is the type of ecosystem example where advanced financial services, payments, and insurance products are setting a global example for how to reinvent customer experiences,” said Tim Attia, CEO of Slice Labs. “Asia is known for pushing the envelope much earlier in adopting new technologies compared to other countries around the world. This makes our vision for ecosystems powered by on-demand insurance a great option for the region and not a customer experience that is decades in the future.”
About Sompo Holdings (Asia):
Based in Singapore, Sompo Holdings (Asia) Pte. Ltd. is the holding company for its Asia Pacific entities, except Japan and is part of Sompo Holdings headquartered in Tokyo, Japan. With more than 70 years of trusted presence in Asia , our business spreads across 14 markets with over 4,000 employees in the region. We are now the Top 10 Largest Non-Life Insurance Companies in Indonesia and Malaysia, and we have forged strategic partnerships to access a wider network of resources and distribution.
Learn more about SOMPO by visiting www.sompo-asia.com .
About Slice:
Slice Labs Inc. is the insurance engine behind tomorrow’s cloud-based, on-demand digital services ecosystems for the new economy. Through the Slice Labs Insurance Cloud Services (ICS) platform, Slice Labs is enabling insurers, technology companies, and other service providers to build truly intelligent and intuitive, pay-as-you-go digital insurance products protecting the insured anytime and anywhere. To stay up to date with Slice, visit https://www.slice.is and follow @SliceLabs on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200116005045/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
